JP3251108B2 - Transdermal patch - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to a transdermal patch.

[0002]

BACKGROUND OF THE INVENTION Percutaneous absorption patches absorb a drug into the body by distributing, diffusing, and transferring the drug from the base of the patch or drug reservoir to the skin and into the blood. Therefore, it is known that the amount of the drug that is transferred to the skin varies depending on the state of the drug in the base. In particular, the higher the concentration of the drug with respect to the saturation solubility in the adhesive base, the higher the drug transfer rate to the skin, and further, the state in which the drug concentration in the adhesive base is higher than the saturation solubility, that is, in a supersaturated state. It is known that transmission performance is increased.

[0003] For the above reasons, transdermal patches have been proposed in which the drug concentration in the adhesive base is increased to precipitate drug crystals, and furthermore, the drug is placed in a supersaturated state exceeding the saturation solubility (Japanese Patent Application Laid-open No. Sho. JP-A-60-16916, JP-A-60-1
85713, JP-A-63-35521, JP-A-63-93714).

[0004] However, a transdermal patch in a supersaturated state is reduced due to a decrease in the supersaturated state during distribution.
There is a problem that drug crystals are precipitated and the permeation performance is reduced. In addition, the patch on which the drug crystals are precipitated requires the drug to be contained in the adhesive base at a supersaturation concentration or higher, and the amount of drug per preparation increases and the cost increases.
Patches that are deposited slowly after reaching the supersaturated concentration level have the problem that the production efficiency is significantly reduced because it takes time to precipitate.

In addition to the above-mentioned patent publications, JP-A-62-273913 and JP-A-63-63913 disclose a method for producing a transdermal absorption preparation in which a drug having a saturation concentration or higher is dispersed in an adhesive base.
No. 2,273,913, all have the following problems.

In the method of precipitating a drug after supersaturating the drug in the base, it takes a long time to precipitate the crystal. Therefore, when precipitating the crystal before distribution, the production time becomes extremely long. When crystals are deposited at the distribution stage, there is a problem that some crystals precipitate and some do not when they reach the user's hand. The method of precipitating drug crystals in a dispersed state is problematic in that it is extremely difficult to uniformly disperse the crystals when the viscosity of the adhesive base or the adhesive base solution is high, and it is difficult to produce a uniform quality preparation. was there.

Further, there has been disclosed an estradiol-containing patch wherein the pressure-sensitive adhesive layer comprises an acrylic pressure-sensitive adhesive containing estradiol and polyvinylpyrrolidone, and a cloth is laminated on the side of the pressure-sensitive adhesive layer opposite to the surface in contact with the skin. (JP-A-2-237268). This prevents crystallization of estradiol by including a predetermined amount of polyvinylpyrrolidone.

However, when the pressure-sensitive adhesive is mainly composed of 2-ethylhexyl acrylate described in the examples, there is a problem that the skin is irritated due to exfoliation due to excessively strong adhesive force. However, there is a problem that the drug permeability is greatly reduced because a breathable cloth material is used.

[0009]

SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned drawbacks, and has as its object to contain a supersaturated drug exceeding the solubility of the adhesive in the adhesive. Another object of the present invention is to provide a transdermal patch that can maintain its supersaturated state stably for a long period of time, has excellent sticking properties, and does not cause skin irritation or pain at the time of peeling.

[0010]

[Means for Solving the Problems]

In the transdermal patch of the present invention, an adhesive layer comprising an adhesive and a drug is laminated on one surface of a support.

Examples of the support include cellulose acetate, ethyl cellulose, polyethylene, polypropylene, polyvinyl chloride, vinyl acetate-vinyl chloride copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl acetate copolymer. Resin film such as carbon monoxide copolymer, ethylene-butyl acrylate-carbon monoxide copolymer, polyvinylidene chloride, polyurethane, nylon, polyethylene terephthalate, polybutylene terephthalate, aluminum sheet, etc. These may be a laminated sheet, or may be laminated with a woven or nonwoven fabric.

The pressure-sensitive adhesive comprises one of a silicone pressure-sensitive adhesive and an acrylic pressure-sensitive adhesive, and polyvinylpyrrolidone. As the silicone-based pressure-sensitive adhesive, “Shirasukon 355” manufactured by Dow Corning Co., Ltd. is commercially available.

Further, the acrylic adhesive, dodecyl methacrylate - DOO and octyl methacrylate least one methacrylates selected from the group consisting of - DOO compound 60 mole
% And at least 40 mol% of one or more acrylate compounds selected from the group consisting of dodecyl acrylate and octyl acrylate.

The octyl methacrylate includes n
-Octyl methacrylate and 2-ethylhexyl methacrylate. Examples of the octyl acrylate include n-octyl acrylate and 2-ethylhexyl acrylate.

In the above-mentioned acrylic copolymer, when the amount of one or more methacrylate compounds selected from the group consisting of dodecyl methacrylate and octyl methacrylate is reduced, the adhesive strength is increased and the skin is irritated.
It is limited to 0 mol% or more .

When the molecular weight of the polyvinylpyrrolidone is too small, the supersaturated state of the drug in the adhesive is destroyed, and the amount of the drug permeated through the skin is reduced. When the molecular weight is too large, the diffusion of the drug in the adhesive layer is inhibited. 10,000 to 50
Limited to 100,000.

If the amount of the above-mentioned polyvinylpyrrolidone is too small, the supersaturated state of the drug cannot be maintained, and if it is too large, the diffusion of the drug is inhibited. Therefore, the amount is limited to 5 to 20 parts by weight with respect to 100 parts by weight of the adhesive. Is done.

In preparing the pressure-sensitive adhesive used in the present invention, solution polymerization of a required monomer is usually carried out in the presence of a polymerization initiator. However, the polymerization form is not limited to this. The polymerization reaction conditions are appropriately selected mainly depending on the type of the monomer.

In the case of carrying out solution polymerization, for example, ethyl acetate or another general polymerization solvent is added to a predetermined amount of a required monomer, and an azobis-based polymer, a peroxide, and a solvent are added in a reactor equipped with a stirring device and a cooling reflux device. The reaction may be performed at 70 to 90 ° C. for 8 to 40 hours in a nitrogen atmosphere in the presence of a polymerization initiator such as an oxide. The monomer and the solvent may be charged at once or may be divided and charged as appropriate. It is preferred that the polymerization initiator is appropriately divided and charged depending on the progress of the reaction.

As the azobis-based polymerization initiator, for example, 2,2′-azobis-iso-butyronitrile,
Examples thereof include 1,1′-azobis (cyclohexane-1-carbonitrile) and 2,2′-azobis- (2,4-dimethylvaleronitrile). Examples of the peroxide-based polymerization initiator include peroxides. Lauroyl, benzoyl peroxide,
Di (ter-butyl) peroxide and the like.

The constitution of the pressure-sensitive adhesive used in the present invention is as described above, but if necessary, a tackifier resin may be added. As the tackifying resin, for example, rosin resin, rosin resin derivative, terpene resin, terpene phenol resin, aliphatic petroleum resin, aromatic petroleum resin, alicyclic petroleum resin, cumarone indene resin, alkylphenol resin And xylene resin.

As the rosin-based resin, a resin mainly containing a mixed melt of a monovalent carboxylic acid having an alkylhydrophenanthrene nucleus is preferably used. As the derivative of the rosin-based resin, hydride, disproportionate, dimerization, esterification, etc. of the rosin-based resin are preferably used.
(Manufactured by Arakawa Chemical Co., Ltd.).

As the terpene resin, for example, α-
Those mainly containing a cyclic terpene such as pinene, β-pinene, camfer and dipentene are preferably used, and commercially available products are YS Resin A, YS Resin PX (all manufactured by Yasuhara Yushi Co., Ltd.), picolite A, picolite S (all manufactured by Hercules) and the like.

As the terpene phenol resin, those obtained by binding phenol to the terpene resin by a Friedel-Crafts reaction or further condensing with formalin are preferably used. Commercially available products include Tamanol 800 (Arakawa Chemical Co., Ltd.) ), YS Polystar (manufactured by Yasuhara Yushi), Sumilite PR-12603 (manufactured by Sumitomo Durets) and the like.

The above-mentioned aliphatic petroleum resin is a tackifying resin mainly composed of an aliphatic compound using petroleum as a raw material, and commercially available products include Escolets (manufactured by Tonen Petrochemical Co., Ltd.) and Hilets (manufactured by Mitsui Petrochemical Co., Ltd.) ), Quinton (manufactured by Zeon Corporation), Tackirole (manufactured by Sumitomo Chemical Co., Ltd.) and the like.

The aromatic petroleum resin is a tackifying resin mainly composed of an aromatic compound using petroleum as a raw material, and commercially available products include petrozine (manufactured by Mitsui Petrochemical Co., Ltd.) and neopolymer (manufactured by Nippon Synthetic Resin Co., Ltd.). ), Petcol (manufactured by Tosoh Corporation), High Resin (manufactured by Toho Petrochemical Co., Ltd.) and the like.

The alicyclic petroleum resin is a tackifying resin mainly composed of an alicyclic compound using petroleum as a raw material, and commercially available products include Alcon (manufactured by Arakawa Chemical Co., Ltd.).

The above-mentioned coumarone indene resin is a resin mainly obtained by copolymerizing coumarone or indene, and commercially available products include Coumarone NG (manufactured by Nippon Steel Chemical Co., Ltd.) and Coumarone RG (manufactured by Nippon Steel Corporation). No.

The above alkylphenol resin is pt-
It is a product obtained by condensing butylphenol and acetylene, and commercially available products include Tamanol 101 and 130 (manufactured by Arakawa Chemical Co., Ltd.) and Hitanol-1501 (manufactured by Hitachi Chemical Co., Ltd.).
Tack rolls 101 and 103 (manufactured by Sumitomo Chemical Co., Ltd.) and the like.

The above xylene resin is obtained by polymerizing a resin containing xylene as a main component, and commercially available products include Nicanol A-70, HP-70 (manufactured by Mitsubishi Gas Chemical Company), National Xylene (Matsushita Electric Works, Ltd.) Manufactured).

Of the above tackifying resins, ester gum and YS resin are particularly preferred.

In the pressure-sensitive adhesive layer, if the amount of the tackifying resin is small, sufficient initial adhesive strength is not exhibited, and if the amount is large, the cohesive strength is reduced and adhesive residue is generated, and the skin is stained at the time of peeling. 10 to 40 parts by weight per 100 parts by weight is preferred.

The drug is not particularly limited as long as it has a steroid skeleton as a main skeleton. Examples of such a drug include estradiol, progesterone, norethisterone, corticosteroid, testosterone, norgestrel, and desogestrel. No. As the drug, 17-β-estradiol and norethisterone acetate are particularly preferable. The term "main skeleton" as used herein refers to a substance in which the sum of the molecular weights of the side chain portions is smaller than the molecular weight of the portion forming the steroid skeleton.

If the amount of the above-mentioned drug is too small, the necessary amount of skin permeation cannot be obtained and the drug effect is lost, and if it is too large, crystals precipitate in the base and the amount of skin permeation decreases, resulting in poor medicinal effect. The amount is preferably 3 to 7 parts by weight based on 100 parts by weight of the adhesive.

If necessary, a transdermal absorption enhancer such as N-lauroylsarcosine and maleic acid may be added to the pressure-sensitive adhesive layer. When the amount of the percutaneous absorption enhancer is reduced, the effect is not exhibited, and when the amount is increased, the adhesiveness of the pressure-sensitive adhesive is reduced, and the pressure-sensitive adhesive is easily peeled at the time of sweating. Therefore, the amount is preferably 3 to 5 parts by weight based on 100 parts by weight of the pressure-sensitive adhesive.

The thickness of the pressure-sensitive adhesive layer is not particularly limited. However, when the pressure-sensitive adhesive layer is thin, the required amount of drug cannot be contained. When the pressure-sensitive adhesive layer is thick, the drug contained in the pressure-sensitive adhesive layer near the support is effective. 30 ~ 200μ
m is preferred.

The constitution of the transdermal patch of the present invention is as described above, and its production can be carried out by a conventionally known method for producing an adhesive tape. A typical example is a solvent coating method, and other examples include a hot melt coating method and an emulsion coating method. When performing solvent coating, for example, a predetermined amount of an adhesive, a drug and a transdermal absorption enhancer are dissolved or dispersed in a solvent such as ethyl acetate, and the obtained liquid is applied to a support, a method of drying, and a method of peeling. A method in which the composition is coated on paper, dried, and then transferred onto a support is preferably used. This release paper may be used to protect the adhesive layer of the patch until use.

The above-mentioned transdermal patch is cut into a predetermined shape and stored and stored in a packaging material. The packaging material is preferably a material that does not transmit or hardly transmits oxygen. The degree is 0 to 100 [cc / m ² · atm · 24 hrs] (25
° C). Examples of such a material include an aluminum foil whose surface is coated with polyethylene terephthalate or polyethylene, and a laminated film of polyvinylidene chloride and polyvinyl chloride.

Further, in order to enhance the stability of the drug content, it is preferable to enclose a deoxidizer in the packaging material. As the oxygen scavenger, iron-based, hydrosulfide-based, ascorbic acid-based, and BHT (butylhydroxytoluene) -based ones can be used, and commercially available products such as Agelace (manufactured by Mitsubishi Gas Chemical Company) and freshness preservative F (Toppan) Printing Co., Ltd.).

When the transdermal patch of the present invention is difficult to apply due to insufficient adhesive strength, the adhesive may be fixed with an adhesive tape after the application. Examples of such an adhesive tape include a bandage of the Japanese Pharmacopoeia, a micropore tape (manufactured by 3M), and Utokuban (manufactured by Yutoku Pharmaceutical).

[0042]

Next, embodiments of the present invention will be described. Hereinafter, “parts” means “parts by weight”. Example 1 69.5 parts (10 mol%) of dodecyl methacrylate (hereinafter referred to as DMA), 46 parts (10 mol%) of 2-ethylhexyl acrylate (hereinafter referred to as EHA)
And 396 parts (80 mol%) of 2-ethylhexyl methacrylate (hereinafter referred to as EHM) to a separable flask equipped with a stirrer and a cooling device, and further adding ethyl acetate to the solution under a nitrogen atmosphere under a nitrogen atmosphere.
Temperature, and 2 parts of lauroyl peroxide were added to cyclohexane 1
The solution dissolved in 00 parts was divided into 10 parts, and one of them was added to a separable flask to start polymerization. After the start of polymerization, 5
From the hour, the remaining 9 was added at hourly intervals, and the reaction was continued for an additional 19 hours after the addition was completed. After the start of the reaction for viscosity adjustment, polymerization was carried out for a total of 40 hours while adding 27 parts of ethyl acetate 5 times every 5 hours, and the solid content concentration was 50% by weight.
Was obtained.

15 parts by weight of 17-β-estradiol and 10 parts by weight of polyvinylpyrrolidone having an average molecular weight of 1.2 million were added to 100 parts by weight of the solid content of the acrylic copolymer, and the mixture was uniformly mixed with a dissolver. Then, a mixed solution was obtained. The obtained mixed solution is applied on a silicon-treated polyethylene terephthalate film (thickness: 40 μm), dried at 60 ° C. for 30 minutes to form an adhesive layer having a thickness of 60 μm, and then a thickness of 50 μm.
m, the pressure-sensitive adhesive layer was transferred onto the ethylene-vinyl acetate copolymer layer of the polyethylene terephthalate-ethylene-vinyl acetate copolymer laminated film to obtain a transdermal patch of the present invention.

(Example 2) Except that polyvinylpyrrolidone was added to 100 parts by weight of the solid content of the acrylic copolymer of Example 1 so that the concentration in the solid content was 7 parts by weight, to obtain a mixed solution. A transdermal patch was obtained in the same manner as in Example 1.

Example 3 The procedure of Example 1 was repeated except that polyvinylpyrrolidone was added in an amount of 17 parts by weight to 100 parts by weight of the solid content of the acrylic copolymer in Example 1 to obtain a mixture. Similarly, a transdermal patch was obtained.

Example 4 Norethithrone acetate was added to 10 parts by weight of 100 parts by weight of the solid content of the acrylic copolymer of Example 1 in place of 17-β-estradiol to obtain a mixed solution. Except for this, a transdermal patch was obtained in the same manner as in Example 1.

Example 5 The procedure of Example 1 was repeated, except that polyvinylpyrrolidone having an average molecular weight of 4,000,000 was added to the acrylic copolymer solution of Example 1 in place of polyvinylpyrrolidone having an average molecular weight of 1.2 million to obtain a mixed solution. A transdermal patch was obtained in the same manner as in Example 1.

(Example 6) A silicone-based pressure-sensitive adhesive ("Silascon 355" manufactured by Dow Corning) was used as the pressure-sensitive adhesive, and a mixture obtained by adding 4 parts by weight of 17-β-estradiol was obtained. A transdermal patch was obtained in the same manner as in Example 1.

Comparative Example 1 The procedure of Example 1 was repeated, except that polyvinylpyrrolidone having an average molecular weight of 600,000 was added to the acrylic copolymer solution of Example 1 in place of polyvinylpyrrolidone having an average molecular weight of 1.2 million to obtain a mixed solution. A transdermal patch was obtained in the same manner as in Example 1.

Comparative Example 2 The procedure of Example 1 was repeated, except that polyvinylpyrrolidone having an average molecular weight of 6,000,000 was added to the acrylic copolymer solution of Example 1 in place of polyvinylpyrrolidone having an average molecular weight of 1.2 million to obtain a mixed solution. A transdermal patch was obtained in the same manner as in Example 1.

Comparative Example 3 A transdermal patch was prepared in the same manner as in Example 1 except that 1 part by weight of polyvinylpyrrolidone was added to the acrylic copolymer solution of Example 1 to obtain a mixed solution. I got

Comparative Example 4 A transdermal patch was prepared in the same manner as in Example 1 except that 25 parts by weight of polyvinylpyrrolidone was added to the acrylic copolymer solution of Example 1 to obtain a mixed solution. Obtained.

(Comparative Example 5) A transdermal patch was obtained in the same manner as in Comparative Example 1 except that 10 parts by weight of norethithrone acetate was added instead of 17-β-estradiol to obtain a mixed solution.

Comparative Example 6 A transdermal patch was obtained in the same manner as in Comparative Example 2, except that 10 parts by weight of norethisrone acetate was added instead of 17-β-estradiol to obtain a mixed solution.

Comparative Example 7 A transdermal patch was obtained in the same manner as in Comparative Example 3, except that 10 parts by weight of norethisrone acetate was added instead of 17-β-estradiol to obtain a mixed solution.

(Comparative Example 8) A transdermal patch was obtained in the same manner as in Comparative Example 4, except that 10 parts by weight of norethithrone acetate was added instead of 17-β-estradiol to obtain a mixed solution.

Comparative Example 9 97.4 parts of 2-ethylhexyl acrylate, 2.6 parts of methacrylate, 0.1 part of polyethylene glycol dimethacrylate, 1.0 part of benzoyl peroxide and 100 parts of ethyl acetate were stirred with a stirrer and cooled. The mixture was supplied to a separable flask equipped with a device, heated to 60 ° C. in a nitrogen atmosphere, and polymerized for 9 hours to obtain a polymer.
Further, 500 parts of ethyl acetate was added to the polymer to adjust the solid content to 20% by weight to prepare an adhesive solution. After 5 parts by weight of polyvinylpyrrolidone having an average molecular weight of 1.2 million and 2.5 parts by weight of 17-β-estradiol were added to the above-mentioned pressure-sensitive adhesive solution, a silicon-treated polyethylene terephthalate film (40 μm in thickness) was added.
m) applied on top, dried at 60 ° C. for 30 minutes and thickness of 60 μm
Then, the pressure-sensitive adhesive layer is transferred onto the ethylene-vinyl acetate copolymer layer of the polyethylene terephthalate-ethylene-vinyl acetate copolymer laminated film having a thickness of 50 μm, and then transdermally absorbed. A patch was obtained.

Skin Permeation Amount Test The transdermal patches obtained in Examples 1 to 6 and Comparative Examples 1 to 9 were stored immediately after production and for one year in a packaging material, and are shown in FIG. The permeation amount (μg) of the skin was measured by the diffusion cell 1. The diffusion cell 1 is composed of a bottomed cylindrical receptor tank 2 and a bottomed cylindrical donor tank 3 arranged on the tank 2. An opening 4 is provided at the center of the bottom wall of the donor tank 3, and the bottom wall extends in the peripheral direction and is provided with a flange 5. Receptor tank 2
A flange 6 is provided at the upper part of the upper side, and a sampling port 7 protruding laterally is attached to the side wall. The flange 5 and the flange 6 are overlapped facing each other, and the donor tank 3 and the receptor tank 2 are airtightly and concentrically stacked. A magnetic stirrer 9 is placed inside the receptor tank 2.

After a hairless mouse (6 weeks old, ♂) was sacrificed by cervical dislocation, the back skin was immediately peeled off, and the subcutaneous fat and muscle layer were removed to obtain a skin piece 8 of about 5 cm × 5 cm.
The obtained skin piece 8 was sandwiched between the flange 5 and the flange 6 of the diffusion cell 1, and the opening 4 of the donor layer 3 was completely closed by the skin piece 8. The obtained sample is circular (3.14 cm ² )
And cut the skin piece 8 so that the adhesive layer is in contact with the skin piece 8.
Affixed to the center.

The receptor layer 2 was filled with the receptor solution, placed in a thermostat maintained at a temperature of 37 ° C., and stirred by rotating the magnet stirrer 9 with a magnet stirring device. Twenty-four hours after the start of the test, 1 ml of the receptor solution was sampled from the sampling port 7, and the amount of 17-β-estradiol in the sampled receptor solution was measured by high-speed chromatography. The results are shown in Table 1. When collecting the receptor liquid, the receptor liquid was replenished after the collection. The test was performed with n = 3, and the average value was calculated.

The receptor solution was NaH ₂ PO ₄ 5 × 10 ^-4
mol, Na ₂ HPO ₄ 2 × 10 ^-4 mol, NaCl 1.5 × 10 ^-1 mol and gentamicin 10 ppm
It was obtained by dissolving 20 parts of polyethylene glycol 400 in 80 parts of an aqueous solution adjusted to pH 7.2 by adding an aqueous solution.

Skin Adhesion Test Using the patches obtained in Examples 1 to 6 and Comparative Examples 1 to 9 and a plaster (standard patch) of the Japanese Pharmacopoeia, the following test was performed on 10 healthy male volunteers. After the evaluation, evaluation was performed according to the following criteria, and the results are shown in Tables 2 and 3. [Test method] The above patch was applied to the left and right upper arms in a 5 mm square, and the patch was maintained for 48 hours without bathing. Then, the sticking property (peeling state) at 24 hours and 48 hours after sticking was visually observed. evaluated. [Judgment Criteria] 5: No peeling was observed in all subjects (peeling area less than 20% is acceptable) 4: 1-3 subjects with a peeling area of 20% or more 3: Half of subjects with a peeling area of 20% or more Above (exfoliation 1
2: 30% to 80% of subjects with peeling area of 20% or more (3 or less of peeling) 1: All subjects with peeling area of 20% or more (7 or less of peeling) 0: 8 or more peeling was observed Was

Skin irritation test Using the transdermal patches obtained in Examples 1 to 6 and Comparative Examples 1 to 9 and the adhesive plaster (standard patch) of the Japanese Pharmacopoeia, the following test was carried out for 10 healthy males. Was evaluated according to the following criteria (based on the Draize method, erythema criteria), and the results of the most frequent values are shown in the table. [Test method] The above patch was applied to the left and right upper arms in a 5 mm square, and was applied for 48 hours without bathing (4 hours after application, 12 hours after application).
After a period of time, a load exercise for 30 minutes was carried out to cause sweating), and then the skin condition was visually observed 30 minutes after peeling and 24 hours after peeling. [Criterion criteria] 0: No erythema, 1: Very mild erythema (at a barely perceptible level), 2: Obvious erythema, 3: Medium to strong erythema

[0064]

[Table 1]

[0065]

The composition of the transdermal patch of the present invention is as described above, and the pressure-sensitive adhesive contains a supersaturated drug exceeding the solubility of the pressure-sensitive adhesive, and the supersaturated state is stable for a long period of time. It can be maintained and has excellent sticking properties and does not cause skin irritation or pain when peeled off.

[0066]

[Brief description of the drawings]

FIG. 1 is a perspective view of a diffusion cell used for a skin permeability test.

[Explanation of symbols]

 DESCRIPTION OF SYMBOLS 1 Diffusion cell 2 Receptor tank 3 Donor tank 4 Opening 5,6 Flange 7 Sampling port 8 Skin piece

Claims (1)

(57) [Claims] A transdermal patch comprising a pressure-sensitive adhesive layer comprising a pressure-sensitive adhesive and a drug laminated on one surface of a support, wherein the pressure-sensitive adhesive is selected from the group consisting of dodecyl methacrylate and octyl methacrylate. One or more selected methacrylates
Pressure sensitive adhesive and silicone comprising an acrylic copolymer comprising at least 60 mol% of an acrylate compound and at least 40 mol% of at least one acrylate compound selected from the group consisting of dodecyl acrylate and octyl acrylate A transdermal patch comprising 100 parts by weight of any one of a series of pressure-sensitive adhesives and 5 to 20 parts by weight of polyvinylpyrrolidone having a molecular weight of 1,000,000 to 5,000,000.